Immix Biopharma Inc (IMMX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Immix Biopharma Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 8.30 $ — 63% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 139.9% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 1
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.71 | -0.87 – -0.57 | 0 | 20.8% | 8 |
| 12/31/2027 | -0.84 | -1.43 – -0.08 | 38 | -19.2% | 7 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.17 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.07 | – | 0 | 1,820.00 | -5,012.50 | -2 | -2 |
| 2025: Q1 | -0.06 | – | 0 | – | – | -2 | -2 |
| 2025: Q2 | -0.09 | – | 0 | – | – | -5 | -5 |
| 2025: Q3 | -0.11 | – | 0 | – | – | -6 | -6 |
| 2025: Q4 | -0.15 | – | 0 | -100.00 | – | -11 | -11 |
| 2026: Q1 | -0.14 | – | 0 | – | – | -10 | -10 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 0 | -1 | -1 | -0.29 | -1 | -4 | 1 |
| 2020 | 0 | 0 | -1 | -0.15 | 0 | -5 | 1 |
| 2021 | 0 | -1 | -24 | -6.64 | -2 | 18 | 18 |
| 2022 | -90 | -8 | -8 | -0.59 | -7 | 13 | 15 |
| 2023 | 0 | -16 | -15 | -0.89 | -11 | 16 | 20 |
| 2024 | 0 | -23 | -22 | -0.76 | -15 | 13 | 23 |
| 2025 | 0 | -27 | -29 | -0.89 | -24 | 94 | 105 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Immix Biopharma, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, befasst sich mit der Entwicklung von Chimären-Antigen-Rezeptor-Zelltherapien bei Leichtketten-Amyloidose und immunvermittelten Erkrankungen in den USA und Australien.
| Employees | 21 |
|---|---|
| Headquarters | Los Angeles, CA |
| Address | 11400 West Olympic Boulevard, 90064 Los Angeles, United States |
| Phone | 310 651 8041 |
| Website | immixbio.com |
| IPO Date | 16. Dec 2021 |
| ISIN | US45258H1068 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Ilya Rachman M.B.A., M.D., Ph.D. | Co-Founder, CEO, Chief Scientific Officer & Chairman | 1973 |
| Gabriel Morris B.A. | President, CFO & Director | 1987 |
| Vladimir P. Torchilin D.Sc., MSE, Ph.D. | Scientific Co-Founder | 1947 |
| Graham Ross FFPM, M.D. | Chief Medical Officer & Head of Clinical Development | 1960 |
| David Marks MBBS, Ph.D. | Chief Medical Officer of Cell Therapy | – |
| Mel Davis-Pickett | Head of CMC Technical Development | – |
| Michael A. Grabow | Chief Commercial Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.